



Clearsight Advisors[®]
Investment Banking

Q1 2026

Healthcare and Life Sciences Services Market Monitor

*Market Update, Industry News and Conferences, Sector
Spotlight, and M&A Activity*



Select Industry News

Anthropic Broadens AI Push Into Healthcare and Biopharma

Anthropic expanded Claude's capabilities into healthcare and life sciences with HIPAA-ready tools and deeper biopharma solutions, aiming to accelerate clinical workflows, regulatory processes, and end-to-end R&D productivity across providers, payers, and biopharma customers. ([Link](#))¹

Dr. James Burt Joins ProductLife Group as CEO

ProductLife Group appointed Dr. James Burt as CEO, adding deep experience in global pharma leadership to support international expansion and further strengthen regulatory, clinical, quality, and digital service capabilities across the full product lifecycle and geographies. ([Link](#))²

FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases

The FDA launched a new framework to accelerate approvals for individualized ultra-rare disease therapies, creating flexible evidence standards where trials are impractical and aiming to enable faster development of gene- and RNA-based precision treatments for patients. ([Link](#))³

Inflexion Augments Healthcare Focus with Hire of Industry Veteran, John DiGiovanni

Inflexion appointed John DiGiovanni as Head of Healthcare, adding seasoned global private equity expertise to accelerate healthcare investing, platform scaling, and value creation across HCIT, tech-enabled services, and diversified biopharma portfolios. ([Link](#))⁴

IQVIA Unveils IQVIA.ai, an Agentic AI Platform Powered by NVIDIA Targeting Life Sciences Decision Making

IQVIA launched an NVIDIA-powered, agentic AI platform that unifies proprietary data, advanced analytics, and end-to-end workflows, enhancing productivity, automating decision-making, and accelerating R&D, commercialization, and operational efficiency for biopharma and medtech clients ([Link](#))⁵

US Biotech Sector Poised for 2026 Rebound as IPO Interest Rises from 2025 Trough

U.S. biotech is expected to rebound in 2026 as IPO activity rebounds, supported by easing interest rates, improving investor sentiment, and reduced regulatory uncertainty following a prolonged sector downturn. ([Link](#))⁶

Upcoming Conferences

[Email ClearSight's sector leadership to set up a meeting](#)

Asembia's AXS26 Summit

April 26th – 30th – Las Vegas, NV

[Learn more](#)

DIA 2026 Global Annual Meeting

June 14th – 18th – Philadelphia, PA

[Learn more](#)

Sector Leadership



Greg Treger
Managing Director
[Email Greg](#)



Tory Steel
Managing Director
[Email Tory](#)



Austin Kuhn
Director
[Email Austin](#)



Jonathan Holland
Vice President
[Email Jonathan](#)



Target

Tegria

(Providence St. Joseph Health)

Acquirer

Altaris

Deal Commentary

- Tegria is a leading provider of outsourced IT services, supporting healthcare providers and payers as they seek to modernize their technology infrastructure and reduce operating costs
- The acquisition positions Tegria for future organic and inorganic growth as a standalone platform

Transaction Summary

On January 6th, 2026, Altaris announced its acquisition of Tegria. Tegria will operate as a wholly owned portfolio company of Altaris, gaining access to new capital and growth opportunities, while continuing to serve Providence as a preferred technology services partner.

Clearsight advised Tegria on this transaction

Transaction Information

Announced Date	January 6, 2026
Deal Type	Buyout
<i>Target Information</i>	
Year Founded	2020
Target HQ	Spokane, WA
# of Employees	~1,200

Target

Stratis Group

Acquirer

Nexus Health / Lockwood

(Ares)

Deal Commentary

- Stratis Group is a consulting firm specializing in commercialization strategy, market access, patient services, and analytics for pharmaceutical, biotechnology, and physician network clients
- The acquisition strengthens Nexus Health's ability to deliver integrated, data-driven solutions that support clients from early commercialization planning through launch and lifecycle optimization

Transaction Summary


On March 17th, 2026, Nexus Health, part of the Lockwood Group, announced its acquisition of Stratis Group. The acquisition adds to Nexus Health's market access capabilities and complements Lockwood's medical affairs, commercialization, access, and oncology education offerings for life sciences organizations.

Clearsight advised Stratis on this transaction

Transaction Information

Announced Date	March 17, 2026
Deal Type	Acquisition (Add-on)
<i>Target Information</i>	
Year Founded	2014
Target HQ	Palm Beach Gardens, FL
# of Employees	~100

Healthcare and Life Sciences Services Deal Volume¹



¹ Time series data based on Clearsight's custom PitchBook screen intended to show trends over time and should be interpreted as directional regarding deal volume. Please email the Clearsight team for specific screen-related questions.



Date	Target	Buyer	Summary
3/30/2026	RND OptimizAR	GeBBS (EQT)	<ul style="list-style-type: none"> RND OptimizAR is a specialized provider of revenue cycle management services targeting the durable medical devices and home medical equipment markets
3/30/2026	Dolon	Prescient (Bridgepoint)	<ul style="list-style-type: none"> Dolon is a pricing and market access consultancy providing rare disease clients with expertise in value strategy, pricing, and access policy
3/27/2026	HealthTech Solutions	HMA (BPOC)	<ul style="list-style-type: none"> HealthTech Solutions is a provider of Medicaid-focused technology and analytics solutions assisting state agencies in systems modernization, reporting, and compliance
3/25/2026	Optimum Healthcare IT (Achieve)	Infosys	<ul style="list-style-type: none"> Optimum Healthcare IT is an IT consulting firm offering enterprise application services, digital transformation, and workforce management to healthcare organizations
3/17/2026	Stratis Group	The Lockwood Group (Ares)	<ul style="list-style-type: none"> Stratis Group is a consulting firm specializing in commercialization strategy, market access, patient services, and analytics for pharmaceutical, biotechnology, and physician network clients
3/10/2026	Ostro	Veeva Systems	<ul style="list-style-type: none"> Ostro is a patient engagement and telemedicine platform designed to streamline the patient journey through consumer engagement and provider education
3/10/2026	Moxe Health	BV Investment Partners	<ul style="list-style-type: none"> Moxe Health is an EHR-neutral data exchange platform securely providing payers and providers with high-quality clinical data
2/24/2026	Access Infinity	CBPE Capital	<ul style="list-style-type: none"> Access Infinity is a market access consultancy combining consulting expertise with digital platforms to help pharmaceutical companies launch and price their products

ClearSight acted as advisor to Stratis Group and Tegria on their respective transactions

Source: Public filings as of 31-Mar-2026, Capital IQ, Pitchbook

4 | ClearSight Monitor | Healthcare and Life Sciences Services | Q1 2026



Date	Target	Buyer	Summary
2/17/2026	Pivot Point Consulting <i>(Highspring)</i>	Innovative Consulting Group <i>(SV Health)</i>	<ul style="list-style-type: none"> Pivot Point Consulting is an IT consulting firm providing advisory, managed services, and talent solutions in one integrated platform across healthcare organizations
2/3/2026	Rare Patient Voice	Konovo <i>(Frazier)</i>	<ul style="list-style-type: none"> Rare Patient Voice is a recruitment platform connecting patients with organizations conducting market research, health economics outcomes research, and clinical trials
2/2/2026	Bridge Medical Consulting	Red Nucleus <i>(THL)</i>	<ul style="list-style-type: none"> Bridge Medical Consulting is a health economics and outcomes research consultancy supporting global pharmaceutical and biotechnology companies
1/20/2026	ROI Healthcare Solutions	Acuvance <i>(Trinity Hunt)</i>	<ul style="list-style-type: none"> ROI Healthcare Solutions is a provider of specialized ERP implementation, optimization, and program management services for hospitals
1/12/2026	Zenith Access Network	Windrose Consulting Group	<ul style="list-style-type: none"> Zenith Access Network is a boutique healthcare consultancy specializing in pricing, market access, and reimbursement solutions
1/9/2026	Bruder Consulting & Venture Group	Dark Horse Consulting <i>(WestView)</i>	<ul style="list-style-type: none"> Bruder Consulting & Venture Group is a strategic advisory firm assisting in the development, design, and approval of biomaterials, devices, and combination products
1/9/2026	Uptake Strategies	Prescient <i>(Bridgepoint)</i>	<ul style="list-style-type: none"> Uptake Strategies is a healthcare consultancy helping life sciences organizations optimize their product planning, strategy, capabilities, and launch
1/6/2026	Tegria <i>(Providence St. Joseph Health)</i>	Altaris	<ul style="list-style-type: none"> Tegria is a leading provider of outsourced IT services, supporting healthcare providers and payers as they seek to modernize their technology infrastructure and reduce operating costs

Cleersight acted as advisor to Stratis Group and Tegria on their respective transactions

Source: Public filings as of 31-Mar-2026, Capital IQ, Pitchbook


5 Cleersight Monitor | Healthcare and Life Sciences Services | Q1 2026



About Clearsight

Clearsight’s Healthcare and Life Sciences Practice focuses on ‘Knowledge Economy’ businesses serving life sciences companies, providers, and payers. This ecosystem is innovating across professional services, technology, and data to move healthcare forward.

Clearsight Advisors is an investment banking firm dedicated to driving the Knowledge Economy by providing world-class M&A and capital raising solutions exclusively to growth-oriented Business Services and Technology companies. Clearsight combines deep market insights across software, services, and data. Clearsight Advisors, Inc. is a wholly owned subsidiary of Regions Financial Corporation. All securities are offered exclusively through RF M&A Securities LLC, a registered broker-dealer and member of FINRA and SIPC. For more information about Clearsight, visit www.clearsightadvisors.com.

 1650 Tysons Boulevard
Suite 710
McLean, VA 22102

250 Park Avenue
Suite 600
New York, NY 10177

 703.672.3100

 www.clearsightadvisors.com

 [Clearsight Advisors](#)

Select Transactions

  has been acquired by  <i>part of</i> The Lockwood Group™ <i>a portfolio company of</i> 	  has been acquired by 	  has been acquired by  <i>a portfolio company of</i> 	  has been acquired by 	  has received a strategic investment from 
  has been acquired by 	  has received a strategic investment from 	  <i>portfolio company</i>  Health & Wellness PARTNERS has acquired 	  has received a strategic investment from 	  has been acquired by  <i>a portfolio company of</i> 

This publication has been prepared solely for the use of institutional investors for general information purposes and is not to be construed as: a personalized recommendation; a solicitation or an offer to buy or sell any securities or related financial instruments; legal, tax, financial or accounting advice. Contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Clearsight has no duty to update the information. Certain sections of this publication may contain forward-looking statements that are based on the reasonable expectations, estimates, projections and assumptions of the authors, but forward-looking statements are not guarantees of future performance and involve risks and uncertainties, which are difficult to predict. The names and marks of other companies or their services or products may be the trademarks of their owners and are used only to identify such companies or their services or products and not to indicate endorsement or sponsorship of Clearsight of its services or products. Clearsight Advisors, Inc. is a wholly owned subsidiary of Regions Financial Corporation. All securities are offered through RF M&A Services LLC, a registered broker-dealer and member of FINRA and SIPC. For more information about Clearsight visit www.clearsightadvisors.com.